MATERIALS AND METHODS: The isolate was grown in a bioreactor, inactivated using binary ethyleneimine, adjuvanted with Montanide 71VG, and injected into day-old broiler chickens either with or without booster groups. The following parameters were measured: T lymphocyte profile in the liver, spleen, and thymus; FAdV antibody titer; clinical symptoms; gross and histological alterations in the liver, spleen, and thymus; virus copy number in the liver and cloacal shedding.

RESULTS: Compared to the unchallenged control group, booster (BG), and non-booster (NBG), the challenged control group (CCG) had a larger liver: body weight (BW) ratio, milder clinical signs, gross lesions, and histological alterations. They also had a lower BW. At 7, 21, 35, and 42 days post-inoculation (dpi), the NBG and BG exhibited higher antibody levels than the UCG. At 35 dpi, challenged BG and NBG produced more antibodies than CCG. In BG and NBG, T cells were stimulated in the spleen, thymus, and liver. At 35 and 42 dpi, the challenged BG and NBG showed significantly decreased viral copy numbers in the liver and shedding, respectively, along with increased lymphocyte counts.

Materials and Methods: Convenience sampling was performed in 20 cats from the Gasing Veterinary Hospital in Selangor. Plasma and saliva samples were collected from 15 clinically ill cats and 5 healthy cats subjected to one-step reverse transcription-polymerase chain reaction with primers targeting a highly conserved gene of U3-LTR-gag.

Results: Two clinically ill cats' plasma and saliva samples tested positive for FeLV RNA. Partial nucleotide sequencing and phylogenetic analysis revealed that the current isolates were 94-99% homologous to the previous Malaysian and Japanese FeLV isolates.